| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
NanoViricides, Inc.
$1.21
-0.04 (-3.2%)
Market Cap
27.81 M
EPS
-0.32
P/E Ratio
-
Value Trade
1.15 M
-6.2 %
Week
-21.94 %
1 Month
-23.9 %
3 Month
29.3 %
6 Month
-52.87 %
5 Year
-85.01 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
191.84 K
52 Week Range
0.85 - 2.23
% held by Insiders
2.36 %
% held by Institutions
9.29 %
Enterprise Value
24.80 M
Total Shares
22.98 M
Short %
3.51 %
Float Shares
20.90 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for NanoViricides, Inc.
80Total events
1Upcoming
6Tier-1 (high impact)
2008 – 2026Coverage
Upcoming catalysts 1
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
TBD
▲Orphan Drug DesignationNV-387Designation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NNVC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NNVC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NNVC▼ -3.2%today
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
NanoViricides is preparing to initiate Phase II clinical trials for NV-387, a broad-spectrum antiviral drug aimed at treating measles, amid rising measles cases in the USA and globally. The drug has demonstrated promising in vivo efficacy against the measles virus and has received FDA's Rare Pediatric Disease Drug Designation. The company is currently drafting a clinical trial protocol for submission to the FDA.
Read more →NNVC▼ -14.9%on this news
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering SHELTON, CT Friday
NanoViricides, Inc. has announced a registered direct offering to raise approximately $2 million through the sale of common shares and accompanying warrants. This offering involves a single institutional investor and is scheduled to close around May 18, 2026, pending customary conditions. The company emphasizes its innovative antiviral, NV-387, which has received orphan drug designation, potentially benefiting from market exclusivity and cost offsets. However, the company acknowledges inherent risks related to market and regulatory uncertainties surrounding the completion of the offering.
Read more →NNVC▲ +15.4%on this news
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
NanoViricides, Inc. announced that its antiviral drug NV-387 has been granted Orphan Drug Designation by the US FDA for the treatment of Measles. This designation will expedite regulatory development and provide various incentives. NV-387 has shown strong efficacy in animal models against the Measles virus, which is critical as global cases rise. The company is also pursuing additional designations to enhance its development strategy.
Read more →NNVC▼ -7.9%on this news
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
NanoViricides, Inc. has filed for Orphan Drug Designation for NV-387 as a treatment for MPox with the FDA. If approved, this designation could provide various incentives, including tax credits and market exclusivity. NV-387 has demonstrated effectiveness in animal models and completed a Phase I clinical trial without adverse events. However, there are no approved treatments for MPox, and existing options have shown limited effectiveness.
Read more →NNVCNanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2
NanoViricides emphasizes the urgent need for broad-spectrum antivirals amid a severe influenza wave, particularly due to the ineffectiveness of current vaccines and antivirals. Their drug candidate NV-387 is designed to combat various respiratory viruses, including the new H3N2 variant, and shows superior efficacy compared to existing treatments. A Phase II clinical trial for NV-387 is planned, aiming to establish it as a first-line therapy for respiratory viral infections.
Read more →NNVC▼ -5.4%on this news· ran to -15% by day 3
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close SHELTON, CONNECTICUT / ACCESS Newswire /
NanoViricides, Inc. has announced a registered direct offering and concurrent private placement aimed at raising approximately $6 million through the sale of shares at $1.68 each. The offering includes Series A and Series B warrants that will allow investors to purchase additional shares. The funds will be used for working capital and general corporate purposes, with the closing expected soon, subject to customary conditions. This move highlights NanoViricides' ongoing efforts to advance its antiviral drug development initiatives.
Read more →NNVCNanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City
NanoViricides, Inc. will present at The Inaugural EF Hutton Global Conference in New York City on May 10, 2023. The conference will host key executives from various sectors to engage with institutional investors and media. As a clinical stage company specializing in antiviral therapies, NanoViricides aims to highlight its novel nanomedicine platform during this significant event. The conference is organized by EF Hutton, a global investment bank, providing an exclusive forum for companies to share their initiatives.
Read more →NNVC▲ +63.3%on this news
Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug Shelton, Connecticut --
Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Connecticut -- September 21, 2021 -- NanoViricides, Inc. (NYSE American: NNVC) (the "
Read more →NNVC▼ -12%on this news
NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development Shelton, Connecticut
NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development Shelton, Connecticut - September 14, 2019 -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a global leader in nanomedicines against viruses, announced today that
Read more →NNVCNanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA SHELTON, CONNECTICUT
Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA SHELTON, CONNECTICUT -- November 19, 2020 -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, announced today that
Read more →NNVCNanoViricides is Developing Drugs Against SARS-CoV-2 with an Integrated Approach to Combat COVID-19, as Reported at The LD 500 Virtual Conference Shelton, CT / ACCESSWIRE /
is Developing Drugs Against SARS-CoV-2 with an Integrated Approach to Combat COVID-19, as Reported at The LD 500 CT / ACCESSWIRE / September 4, 2020/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral th
Read more →NNVCNanoViricides, Inc. Investors Who Purchased NNVC Securities After January 2020 And Suffered Losses Greater Than $50,000 Encouraged To Contact Kehoe Law Firm, P.C.
PHILADELPHIA, July 16, 2020 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of NanoViricides, Inc. (“NanoViricides” or the “Company”) (NYSE: NNVC) to determine whether the Company engaged in securities fraud or other un
Read more →NNVCNANOVIRICIDES CLOSES ON $11.5 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK SHELTON, CONNECTICUT - Monday
CLOSES ON $11.5 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK SHELTON, CONNECTICUT - Monday, July 13, 2020 -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedici
Read more →NNVCNanoViricides Announces Pricing of $10.2 Million Registered Direct Offering Shelton, Connecticut
NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering Connecticut -- May 21, 2020 -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, to
Read more →NNVCHonorable Ex-Congressman Todd Rokita Joins the Board of Directors of NanoViricides, Inc. SHELTON, CONNECTICUT
Honorable Ex-Congressman Todd Rokita Joins the Board of Directors of NanoViricides, Inc. SHELTON, CONNECTICUT -- May 18, 2019 -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, announced today that Ho
Read more →NNVCNANOVIRICIDES CLOSES ON $8.625 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK SHELTON, CONNECTICUT - Friday
CLOSES ON $8.625 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK SHELTON, CONNECTICUT - Friday, January 24, 2020 -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanome
Read more →NNVCNanoViricides President Dr. Anil Diwan Provides Responses to Shareholder Questions at the Annual Meeting of Shareholders SHELTON, CONNECTICUT
President Dr. Anil Diwan Provides Responses to Shareholder Questions at the Annual Meeting of Shareholders SHELTON, CONNECTICUT -- December 9, 2019 -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a global leader in nanomedicines against viruses, held its annual meet
Read more →NNVCNanoViricides Completes Licensing for VZV Field which Includes Shingles Drug Development Shelton, Connecticut
NanoViricides Completes Licensing for VZV Field which Includes Shingles Drug Development Shelton, Connecticut - November 4, 2019 -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a global leader in nanomedicines against viruses, announced today that it has completed
Read more →NNVCNanoViricides Announces $2.5 Million Financing in a Registered Direct Offering SHELTON, CONNECTICUT - Wednesday
Announces $2.5 Million Financing in a Registered Direct Offering CONNECTICUT - Wednesday, February 27, 2019 - NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform
Read more →NNVCDATED FEBRUARY 13, 2017 NanoViricides Reports the Company's Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising $5M in New Equity for the Company SHELTON, CONNECTICUT
NanoViricides Reports the Company's Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising $5M in New Equity for the Company SHELTON, CONNECTICUT - February 13, 2017 -- NanoViricides, Inc. (NYSE MKT: NNVC), a global leader in the development of highly
Read more →NNVCNanoViricides, Inc. Completes Purchase of cGMP-compliant Pilot Production Facility
NanoViricides, Inc. Completes Purchase of cGMP-compliant Pilot Production Facility CONNECTICUT - January 7, 2015 - NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), has completed the purchase of the state of the art cGMP-compliant Manufacturing and R&D facility located in
Read more →NNVCNanoViricides Reports that its Director Dr. Milton Boniuk, a Director, Has Invested $5M into the Company in a Convertible Debenture
Reports that its Director Dr. Milton Boniuk, a Director, Has Invested $5M into the Company in a Convertible Debenture WEST HAVEN, Conn., Jul 02, 2014 (BUSINESS WIRE) -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") reported today that Milton Boniuk, MD, the Caroline F.
Read more →NNVCEradicating Viral Diseases May 2014 Marcum conference, New York City Eugene Seymour, MD, MPH Chief Executive Officer " nanoviricide " is a registered trademark of NanoViricides, Inc. All rights reserved - NanoViricides,
NanoViricides, Inc. is a publicly traded company (stock symbol: NNVC, NYSE MKT .) This is not an offering memorandum and should not be construed as such. It is provided as a non - confidential document for informational purposes only. NanoViricides, Inc. ( www.nanoviricides.com )
Read more →NNVCNanoViricides, Inc. Reports its President & Chairman Dr. Diwan Purchased its Common Stock in the Open Market WEST HAVEN, CONNECTICUT
NanoViricides, Inc. Reports its President & Chairman Dr. Diwan Purchased its Common Stock in the Open Market WEST HAVEN, CONNECTICUT -- February 26, 2014 -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), reports that its President & Chairman Dr. Anil Diwan has purchase
Read more →NNVCNanoViricides Announces that It Has Raised $20 Million in a Registered Direct Offering WEST HAVEN, CONNECTICUT - Tuesday, January 21st, 2014 - NanoViricides, Inc. (NYSE MKT: NNVC ) (the Company ) announced today that it
Announces that It Has Raised $20 Million in a Registered Direct Offering WEST HAVEN, CONNECTICUT - Tuesday, January 21st, 2014 - NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") announced today that it has raised approximately $20 Million in a registered direct offering. T
Read more →NNVCNanoViricides CEO Dr. Eugene Seymour to Be Interviewed on Clear Channel DFW 1190AM
WEST HAVEN, CT--(Marketwired - Dec 18, 2013) - NanoViricides, Inc. (NYSE MKT: NNVC) is a development stage company that is creating special purpose nanomaterials to destroy viruses in and on the body. The Company announced today that CEO Dr. Eugene Seymour will be interviewed liv
Read more →NNVCNanoViricides Announces that its Annual Meeting was held on December 9th, 2013; the CEO Presentation is available on the Redesigned Website WEST HAVEN, CONNECTICUT -- December, 11th, 2013 -- NanoViricides, Inc. (NYSE MKT
NanoViricides Announces that its Annual Meeting was held on December 9th, 2013; the CEO Presentation is available on the Redesigned Website WEST HAVEN, CONNECTICUT -- December, 11th, 2013 -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), announced today that the annual
Read more →NNVCNanoViricides Announces that It Now Meets Listing Standards of Major National Stock Exchanges Upon Executing a Reverse Split of its Stock; Also Reports It Has Raised approximately $9.9 Million in a Registered Direct Offe
NanoViricides Announces that It Now Meets Listing Standards of Major National Stock Exchanges Upon Executing a Reverse Split of its Stock; Also Reports It Has Raised approximately $9.9 Million in a Registered Direct Offering WEST HAVEN, CONNECTICUT -- Tuesday, September 10th,
Read more →NNVCPress Release dated
NanoViricides Reports That its CEO was Interviewed on the RedChip Money Report Program on Fox Business News TV Channel Yesterday Evening WEST HAVEN, CONNECTICUT -- July 19, 2013 -- NanoViricides, Inc. (OTC BB: NNVC) (the "Company"), reports that a video interview with its CE
Read more →NNVCNanoViricides announces Retirement of its Series C Convertible Preferred Stock Held by Seaside 88, LP - Company reports having more than two years of cash on hand
NanoViricides announces Retirement of its Series C Convertible Preferred Stock Held by Seaside 88, LP - Company reports having more than two years of cash on hand CONNECTICUT - February 27, 2013 - NanoViricides, Inc. (OTC BB: NNVC) (the "Company"), announced today that it has
Read more →NNVCNanoViricides Announces Completion of Previously Reported $5 Million in Shelf Offering - Company Reports Having More Than Two Years of Cash on Hand
NanoViricides Announces Completion of Previously Reported $5 Million in Shelf Offering - Company Reports Having More Than Two Years of Cash on Hand WEST HAVEN, Conn., Dec 24, 2012 (BUSINESS WIRE) -- NanoViricides, Inc. (OTC BB: NNVC) (the "Company"), announced today that it h
Read more →NNVCEXHIBT 99.1 NanoViricides Raises $5 Million in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand WEST HAVEN, Conn.--(BUSINESS WIRE)-- NanoViricides, Inc. (OTC BB: NNVC) (the Company ), annou
NanoViricides Raises $5 Million in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand WEST HAVEN, Conn.--(BUSINESS WIRE)-- NanoViricides, Inc. (OTC BB: NNVC) (the "Company"), announced today that it has raised $5,000,000, drawing down on its previ
Read more →NNVCNanoViricides Raises $5 Million in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand WEST HAVEN, Conn.--(BUSINESS WIRE)-- NanoViricides, Inc. (OTC BB: NNVC) (the Company ), announced today t
NanoViricides Raises $5 Million in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand WEST HAVEN, Conn.--(BUSINESS WIRE)-- NanoViricides, Inc. (OTC BB: NNVC) (the "Company"), announced today that it has raised $5,000,000, drawing down on its previ
Read more →NNVCNanoViricides Completes a $5 Million Raise in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand
NanoViricides Completes a $5 Million Raise in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand WEST HAVEN, CONNECTICUT, February 9, 2012: NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") announced today that it has received the final tranch
Read more →NNVCNanoViricides Raises an Additional $5 Million in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand
NanoViricides Raises an Additional $5 Million in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand WEST HAVEN, CONNECTICUT - November 3, 2011 -- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that it has raised $5,000,000, dr
Read more →NNVCNanoViricides Raises $2.5M in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand
NanoViricides Raises $2.5M in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand WEST HAVEN, CONNECTICUT - July 27, 2011 -- NanoViricides, Inc. (OTC BB: NNVC) (the "Company"), announced today that it had successfully consummated a closing with Seasid
Read more →NNVCNanoViricides Raises an Additional $2.5M in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand
NanoViricides Raises an Additional $2.5M in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand WEST HAVEN, CONNECTICUT - December 22, 2010 -- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that it had consummated a closing wit
Read more →NNVCNanoViricides Raises an Additional $2.5M in Shelf Offering - The Company Reports It Now Has More than 18 Months of Cash in Hand Press Release Source: NanoViricides, Inc. On Wednesday
NanoViricides Raises an Additional $2.5M in Shelf Offering - The Company Reports It Now Has More than 18 Months of Cash in Hand Press Release Source: NanoViricides, Inc. On Wednesday September 22, 2010, 7:00 am EDT WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC B
Read more →NNVCNanoViricides Raises $5M in Shelf Offering WEST HAVEN, CONNECTICUT -- May 12 th , 2010 -- NanoViricides, Inc. (OTC BB: NNVC.OB ) (the "Company"), announced today that it has raised $5,000,000, drawing down on its previou
NanoViricides Raises $5M in Shelf Offering WEST HAVEN, CONNECTICUT -- May 12th, 2010 -- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that it has raised $5,000,000, drawing down on its previously announced universal registered shelf "Form S-3" offering.
Read more →NNVCSource: NanoViricides, Inc. NanoViricides, Inc. Herpes Study Results Discussed on CBS News Report WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB ) (the "Company"), reported today t
Source: NanoViricides, Inc. NanoViricides, Inc. Herpes Study Results Discussed on CBS News Report WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that the CBS affiliate TV station WBRZ interviewed Professor K. Gus Kousou
Read more →NNVCFireside chat #3 November 13 th About NanoViricides: NanoViricides, Inc. ( www.nanoviricides.com ) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nano
chat #3 November 13th (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to disman
Read more →NNVCE XH IBIT 99.1 Wednesday
NanoViricides - Fireside the first in a series of "Fireside Chats" with Dr. Eugene Seymour, Chief Executive Officer of NanoViricides. weeks ago I emailed Dr. Seymour with several questions about the Company and the state of it's business model. In his reply, Dr. Seymour sugge
Read more →NNVCSUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT (this "Sublease") is made and entered into as of the 31 st day of January 31 st 2007, by and between NanoViricides, Inc., a Nevada corporation (the "Subtenant"), and Kemira Chem
SUBLEASE AGREEMENT (this "Sublease") is made and entered into as of the and between NanoViricides, Inc., a Nevada corporation (the "Subtenant"), and Kemira Chemicals, Inc., a Georgia corporation (the "Sublandlord"). is the tenant of a certain building and improvements (the "P
Read more →NNVCNanoViricides Presents at the Premiere Event of the Year for Connecticut's Technology Leaders
NEW YORK, Sept. 28, 2005 (PRIMEZONE) -- NanoViricides, Inc. (Pink Sheets:NNVC) announced that its President, Dr. Anil Diwan, has been selected to present today to a group of select investors at the Connecticut Venture Group's Annual CVG Angel forum. Only thirty entrepreneurial bu
Read more →NNVCNanoViricides Announces Progress in Development of FluCide-I Influenza Drug
NEW YORK, Sept. 20, 2005 (PRIMEZONE) -- NanoViricides, Inc. (Pink Sheets:NNVC) announced today that the Company is actively developing its first NanoViricide(tm) drug, "FluCide-I(tm)." The Company expects to commence studies in external laboratories within a matter of weeks to ve
Read more →Competitive Position
How NNVC ranks across every disease it competes inCompetitive Position is a premium feature
See how NNVC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial